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Optimal statin type and dosage for vascular
patients
Kosmas I. Paraskevas, MD,a Dimitri P. Mikhailidis, MD,b and Frank J. Veith, MD, FACS,c Athens,
Greece; London, United Kingdom; and New York, NY
Statins are an essential component of the management of patients suffering from vascular diseases. As there is neither any
consensus nor any guidelines regarding this issue, we aimed to define the optimal statin type and dosage for these patients.
MEDLINE was searched for studies comparing different statin types and dosages for vascular patients. In the absence of
adverse effects, rosuvastatin or atorvastatin >20 mg/d is the optimal statin type and dosage for vascular patients. The
management of statin-induced adverse events and the options for statin-intolerant patients are also discussed.
Routine statin treatment is associated with several beneficial effects in vascular patients whether managed conserva-
tively or undergoing open vascular surgery/endovascular interventions. If possible, statins should not be discontinued
before open or endovascular procedures and treatment should be resumed as soon as possible. Future studies should
evaluate the effects of an increased statin loading dose prior to vascular procedures. ( J Vasc Surg 2011;53:837-44.)
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(The discovery of statins (3-hydroxy-3-methylglutaryl
coenzyme A [HMGCoA] reductase inhibitors) approxi-
mately 30 years ago was a revolution in the management of
dyslipidemias.1 It gradually turned out that statins may
exert numerous beneficial actions besides lipid-lowering,
the so-called “statin pleiotropic effects.”2,3 Routine statin
use in vascular patients is associated with several beneficial
effects, whether they are managed conservatively or un-
dergo open surgical or endovascular procedures.4-10 Statins
have been clearly shown to improve outcomes both in
patients with peripheral arterial disease (PAD)5,10 and
those with carotid artery disease.4,8 They are also associated
with beneficial effects in patients undergoing open surgical
or endovascular abdominal aortic aneurysm (AAA) re-
pair.6,7,9
This article aims to: (1) identify the optimal statin type
and dosage for vascular patients; (2) discuss the options for
the management of statin-induced adverse events; (3) iden-
tify possible alternatives for statin-intolerant patients; and
(4) discuss when statin therapy should be stopped preop-
eratively and when it should be resumed postoperatively.
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In this review, “vascular” patients are defined as those
ith noncardiac vascular disease (eg, AAAs, PAD, and
arotid artery disease).
We searched PubMed up to October 5, 2010 for
tudies comparing the efficacy of different statin types and
osages for the vascular patient. Using the search term
statins,” a total of 25,340 references were identified. The
itle of each reference was read. If the reference was relevant
o vascular surgery, endovascular interventions, vascular
isease prevention, or vascular biology, the abstract was
lso read. A total of 927 papers were selected for further
valuation. From these, the full-text paper of those articles
elevant to the topic (n  257) was retrieved when avail-
ble. The reference lists of the gathered reports were also
anually searched for additional studies. Furthermore, the
earch was refined with the terms “statins and peripheral
rterial disease” (343 references), “statins and abdominal
ortic aneurysms” (94 references), and “statins and carotid
rtery disease” (423 references). These references were
hen cross-checked with the previous more general search.
ESULTS
Statins exert several beneficial effects for vascular pa-
ients with AAAs,6 carotid artery disease,4 as well as PAD.10
he effects of routine statin treatment on these patients will
e briefly discussed.
Statins reduce cardiovascular events and mortality
ates. A large meta-analysis (n  90,056 patients; 14 ran-
omized trials), the Cholesterol Treatment Trialists’ Col-
aborators (CTTC), showed that for each 1.0 mmol/L (39
g/dL) decrease in low-density lipoprotein cholesterol
LDL-C), statin treatment was associated with a 12% re-
uction in all-cause mortality (risk ratio [RR], 0.88; 95%
onfidence interval [CI], 0.84-0.91; P  .0001), a 19%
eduction in coronary mortality (RR, 0.81; 95% CI, 0.76-
.85; P .0001), a 23% reduction in myocardial infarction
MI) or coronary death rates (RR, 0.77; 95% CI, 0.74-
.80; P .0001), a 24% reduction in the need for coronary
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March 2011838 Paraskevas et alrevascularization (RR, 0.76; 95% CI, 0.73-0.80; P 
.0001), a 17% reduction in fatal or nonfatal stroke (RR,
0.83; 95% CI, 0.78-0.88; P  .0001), and, combining
these, a 21% reduction in any major cardiovascular event
(RR, 0.79; 95% CI, 0.77-0.81; P .0001) compared with
placebo.11 The proportional reduction in major vascular
events differed significantly (P  .0001) according to the
absolute reduction in LDL-C achieved. Compared with
lower doses, higher-dose statin therapy reduced MIs by a
further 16% and strokes by an additional 18% in patients
with coronary heart disease. After 5 years, 42 (95% CI,
30-55) fewer diabetic patients suffered a major vascular
event per 1000 receiving statin therapy. In another meta-
analysis (n  25 trials; 155,613 patients),12 every 25
mg/dL (0.65 mmol/L) statin-induced reduction in
LDL-C levels resulted in an 11% reduction in mortality
(RR, 0.89; 95% CI, 0.87-0.92), a 14% reduction in major
vascular events (RR, 0.86; 95% CI, 0.84-0.88), a 16%
reduction in major coronary events (RR, 0.84; 95% CI,
0.82-0.86), and a 10% reduction in strokes (RR, 0.90; 95%
CI, 0.86-0.94). The authors concluded that these results
support and extend the CTCC findings. Thus, aggressive
statin treatment is associated with improved cardiovascular
outcomes compared with usual care.11,12 Importantly, the
benefit of intensive treatment is apparent as early as 30 days
after initiation of treatment and is consistent over time.13
As there is neither any consensus or any guidelines
regarding the optimal statin type and dosage for vascular
patients, this review article aimed to answer five important
questions:
(1) Which statin is more effective?
(2) What is the optimal dosage?
(3) What are the side effects of statins and are they dose-
related?
(4) What are the options in statin-intolerant patients?
(5) How should patients’ statin therapy be managed
periprocedurally?
DISCUSSION
Comparing statin types and dosages. Rosuvastatin
(Crestor) is a more potent lipid-lowering agent than ator-
vastatin (Lipitor),14-19 pravastatin (Pravachol),16-21 simva-
statin (Zocor),16-21 lovastatin (Mevacor),17,20 or fluva-
statin (Lescol).17,22 The cost of the different statins is
presented in Table I. Until a few years ago, rosuvastatin was
Table 1. Price of different statin types and dosages in the
5 mg 10 m
Rosuvastatin (30 tablets) $145.90 $145
Atorvastatin (30 tablets) — $94
Simvastatin (30 tablets) $15.88 $19
Lovastatin (30 tablets) — $17
Pravastatin (30 tablets) — $17
Fluvastatin (100 tablets) — —Simvastatin, lovastatin, and pravastatin are now available in generic formulas.
aThis price is for 30 tablets, not 100.ore cost-effective in terms of lipid lowering compared
ith atorvastatin, simvastatin, or pravastatin.23 A retrospec-
ive pharmacoeconomic analysis showed that in terms of
atients achieving lipid goals, rosuvastatin 10 mg was more
ffective at equal or lower cost compared with atorvastatin
0 and 20 mg, pravastatin 20 and 40 mg, branded simva-
tatin 10 to 80 mg, and generic simvastatin 40 and 80
g.24With the recent introduction of generic formulations
f simvastatin, lovastatin, and pravastatin, however, rosuv-
statin may no longer be the most cost-effective option
Table I). Rosuvastatin reduces the incidence of major
ardiovascular events even in apparently healthy persons. In
he Justification for the Use of statins in Prevention: an
ntervention Trial Evaluating Rosuvastatin (JUPITER),
7,802 apparently healthy men and women with LDL-C 
30 mg/dL (3.4 mmol/L) and high-sensitivity C-reactive
rotein (hsCRP) levels 2.0 mg/L were randomly as-
igned to rosuvastatin 20 mg/d or placebo.25 The patients
ere followed up for a median of 1.9 years for the occur-
ence of the combined primary end point (MI, stroke,
rterial revascularization, hospitalization for unstable an-
ina, or death from cardiovascular causes). The rates of the
rimary end point were 0.77 and 1.36 per 100 person-years
or rosuvastatin vs placebo (hazard ratio [HR], 0.56; 95%
I, 0.46-0.69; P  .00001). In more detail, the rates for
osuvastatin vs placebo were 0.17 vs 0.37 for MI (HR,
.46; 95% CI, 0.30-0.70; P  .0002), 0.18 vs 0.34 for
troke (HR, 0.52; 95% CI, 0.34-0.79; P  .002), 0.41 vs
.77 for revascularization or unstable angina (HR, 0.53;
5% CI, 0.40-0.70; P  .00001), 0.45 vs 0.85 for the
ombined end point of MI, stroke, or death from cardio-
ascular causes (HR, 0.53; 95% CI, 0.40-0.69; P 
00001), and 1.00 vs 1.25 for death from any cause (HR,
.80; 95% CI, 0.67-0.97; P  .02).25 Whether hsCRP
evels may be used to identify low- and intermediate car-
iovascular risk patients for statin treatment is a subject of
ebate.26
Rosuvastatin has a similar benefit-risk profile with other
tatins.27,28 Compared with other statins, rosuvastatin has a
imilar low risk of serious muscle damage (myopathy and
habdomyolysis) and no consistent pattern of renal failure
r renal injury, despite a mild transient tubular proteinuria,
s seen with all statins.29 Nevertheless, coadministration of
osuvastatin with vitamin K antagonists, cyclosporine, gem-
brozil, and antiretroviral agents should be carried out with
ed States89
20 mg 40 mg 80 mg
$145.91 $145.90 —
$134.70 $134.70 $134.70
$24.97 $25.48 $26.98
$20.80 $31.84 —
$14.90 $17.26 $18.99
$333.37 $333.37 $117.70aUnit
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Volume 53, Number 3 Paraskevas et al 839caution since a potential pharmacokinetic interaction with
these drugs may increase the risk of rosuvastatin toxicity.30
The next more potent statin is atorvastatin. Atorvasta-
tin is a more potent lipid-lowering agent and may prevent
more cardiovascular events compared with pravastatin31 or
simvastatin32,33 (Table II). Intensive atorvastatin treat-
ment (80 mg/d) is also more cost-effective compared with
intensive simvastatin therapy (80 mg/d).34 Furthermore,
the Treating to New Targets trial reported that intensive
atorvastatin treatment (80 mg/d) reduced cardiovascular
events by an additional 22% when compared with atorva-
statin 10 mg/d.35
One potential disadvantage of atorvastatin is that high
doses have little or no ability to increase HDL-C while
rosuvastatin does.36 This may be a disadvantage in patients
with the metabolic syndrome or diabetes mellitus (DM),
where low HDL-C is common.37
Other studies supported that fluvastatin is more cost-
effective than atorvastatin.38,39 Fluvastatin, however,
achieves target cholesterol levels (LDL-C  100 mg/dL
[2.56 mmol/L]) in a much lower percentage of pa-
tients compared with atorvastatin (13.2% vs 74.4%, re-
spectively).39 Fluvastatin is a less potent cholesterol-
lowering agent than either atorvastatin39 or lovastatin.40
However, unlike other statins, fluvastatin is metabolized by
non-CYP 3A4 pathways and should therefore be preferred
in hepatic failure.41
A recent meta-analysis of the therapeutic equivalence of
statins concluded that a daily dose of atorvastatin 10 mg,
fluvastatin 80 mg, lovastatin 40/80 mg, and simvastatin 20
mg could decrease LDL-C by 30% to 40%.42 In turn,
fluvastatin 40 mg, lovastatin 10/20 mg, pravastatin 20/40
mg, and simvastatin 10 mg could decrease LDL-C by 20%
to 30%.42 Reductions in LDL-C  40% are necessary to
achieve atherosclerosis regression.43 The only two statins
that could reduce LDL-C  40% were rosuvastatin and
Table II. Studies comparing the low-density lipoprotein c
atorvastatin with other statins
Study (year) Inclusion criteria Study de
Sirtori et al31
(2005)
Patients with familial
combined hyperlipidemia
Comparison of the L
effect of 3 month
with atorvastatin 1
pravastatin (20 m
Foody et al32
(2008)
Primary prevention patients
newly initiating
simvastatin of
atorvastatin treatment
Comparison of the n
cardiovascular eve
patients on atorva
mg/d with simva
mg/d.
Foody et al33
(2010)
Hypertensive patients
without prior
cardiovascular disease
Comparison of the n
cardiovascular eve
hypertensive patie
prior cardiovascul
atorvastatin 10 or
simvastatin 20 or
CI, Confidence interval; HR, hazard ratio; LDL-C, low-density lipoproteinatorvastatin at a daily dose of 20 mg or higher.42 cIn summary, in the absence of adverse events, rosuvas-
atin or atorvastatin at a dosage of 20 mg/d is probably
he optimal statin type and maintenance dosage for the
ascular patient.
Adverse events with statins and their relationship to
osage. Themechanisms by which statins induce their side
ffects (eg, myopathy, rhabdomyolysis, hepatotoxicity) are
eviewed elsewhere.44,45 The statin-induced adverse effects
ay be dose-related.46,47 A meta-analysis of prospective,
andomized controlled trials evaluating intensive- and
oderate-dose statin therapy for the reduction of cardio-
ascular events concluded that intensive therapy with ator-
astatin or simvastatin 80 mg was associated with a signifi-
ant increase in the risk for any adverse event (odds ratio
OR], 1.44; 95% CI, 1.33-1.55; P  .001) and adverse
vents requiring discontinuation of therapy (OR, 1.28;
5% CI, 1.18-1.39; P .001).48 Intensive therapy was also
ssociated with an increased risk for abnormal liver function
ests (OR, 4.48; 95% CI, 3.27-6.16; P  .001), and eleva-
ions in creatine kinase activity (OR, 9.97; 95% CI, 1.28-
7.92; P .028). Nevertheless, intensive statin therapy was
lso associated with reductions in cardiovascular death
OR, 0.86; 95% CI, 0.75-0.99; P  .031), MI (OR, 0.84;
5% CI, 0.76-0.93; P  .001), and stroke (OR, 0.82; 95%
I, 0.72-0.94; P .004).48 Atorvastatin is associated with
he greatest and fluvastatin with the lowest risk of adverse
vents. Simvastatin, pravastatin, and lovastatin have inter-
ediate and similar risks of causing adverse events.49 The
elatively rare and usually mild statin-induced adverse ef-
ects are thus counterbalanced by the benefits associated
ith high-dose treatment.
Elevated hepatic transaminase activities have been re-
orted in 0.5% to 2.0% of statin-treated patients and are
ose dependent.50 Elevation of aminotransferase activity is
sually mild and not clinically significant. Accordingly,
tatins should not be discontinued in patients with high
sterol and cardiovascular event lowering effects of
Outcome
C lowering
tment
/d or
Atorvastatin achieved greater reductions in total
(–26.8  11.1% vs –17.6  11.1%, respectively;
P  .05) and LDL-C (–35.9  11.1% vs
–24.5  10.2%, respectively; P  .05) compared
with pravastatin.
er of
etween
10 or 20
20 or 40
Atorvastatin use was associated with fewer
cardiovascular events compared with simvastatin
use (HR, 0.88; 95% CI, 0.83-0.93; P  .001).
er of
etween
ithout
ease on
g/d with
g/d.
The crude cardiovascular event rates were lower for
atorvastatin compared with simvastatin (2.81 vs
3.92 per 100 person-years, respectively; adjusted
HR, 0.91; 95% CI, 0.84-0.98; P  .009).
sterol.hole
sign
DL-
s’ trea
0 mg
g/d).
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March 2011840 Paraskevas et alnotransferase levels with no clinical relevance or attribut-
able to known stable chronic liver conditions.51 Further-
more, elevated transaminase activity has not been linked
with hepatotoxicity and is reversible with dose reduction or
discontinuation of therapy.50-53 Progression to liver failure
due to statin therapy occurs extremely rarely (if ever).50
There is no evidence that statins aggravate existing hepatic
disease.50 Stopping statins due to mild aminotransferase
elevations is therefore not recommended.51 Nevertheless,
cholestasis and active liver disease are (perhaps wrongly)
considered to be contraindications to statin therapy.50
Recent evidence suggests that statins are associated
with a slight increase in the risk of incident DM.54 How-
ever, the benefits associated with statin use outweigh any
adverse effects in patients withmoderate-to-high cardiovas-
cular risk.54 A meta-analysis (n  13 statin trials; 91,140
patients) on the association between statin use and the
development of incident DM concluded that statin use was
associated with a slight increase in the risk of developing
incident DM (OR, 1.09; 95% CI, 1.02-1.17).55 The con-
clusion reached was that the beneficial effects (eg, reduc-
tion in coronary events) associated with statin use outweigh
the low risk of developing DM and do not justify a change
in the management of patients with moderate or high
cardiovascular disease risk or existing cardiovascular dis-
ease. Statins do not seem to increase the risk of developing
cancer.56 However, they should not be used during preg-
nancy, as they may be associated with teratogenic defects.57
Aggressive statin therapy is both effective and safe, even
in older patients.58,59 This is quite important since statin
use in older high-risk patients is associated with more
beneficial effects compared with younger patients.60 In
spite of this, there is evidence that elderly patients fre-
quently receive suboptimal statin therapy.61 Despite an
increase in statin use in the last decade, vascular patients
often still receive suboptimal statin treatment.62 More pre-
cisely, not only is there suboptimal statin use,61 but also
suboptimal statin dosing.63 Statins rarely cause adverse
events, even when administered at high doses. Even when
such adverse events occur, they are usually mild and revers-
ible with dosage reduction.
Options for statin-intolerant patients. The options
for statin-intolerant patients are fully reviewed else-
where.64,65 Briefly, these include (1) use of a different statin
initiated at a lower dose with gradual up-titration; (2) an
alternate daily or weekly dosing of a statin with a long
half-life (eg, rosuvastatin or atorvastatin); and (3) the com-
bination of the lowest tolerated statin with a cholesterol
absorption inhibitor (ezetimibe) and/or bile acid seques-
trant.64,65 However, whether these alternative options
translate into a reduction of cardiovascular effects (as with
high-dose daily statin therapy) remains to be proven.
Perioperative/periprocedural statin therapy. There
is evidence suggesting that statins reduce perioperative, as
well as long-term morbidity and mortality in patients un-
dergoing noncardiac vascular surgery.9 A meta-analysis
(n  223,010 patients) revealed that preoperative statin
therapy considerably reduces postoperative mortality (1.7% Ls 6.1%, respectively; P  .0001), MI (2.9% vs 6.2%,
espectively; P  .001), and stroke rates (2.0% vs 3.3%,
espectively; P .049) compared with statin non-use.66 In
nother study, discontinuation of statin therapy periopera-
ively was associated with a greater than sevenfold increased
isk for the combination of MI and cardiovascular death
HR, 7.5; 95% CI, 2.8-20.1).67 Until recently, the benefi-
ial effects of perioperative statin therapy were based on
etrospective studies. A recent prospective, double-blind, pla-
ebo-controlled trial verified these findings.68 Preoperative
xtended-release fluvastatin 80 mg/d treatment prior to
oncardiac vascular surgery (AAA repair, aortoiliac recon-
truction, lower limb arterial reconstruction, or carotid
ndarterectomy) was associated with a reduction in post-
perative myocardial ischemia (10.8% vs 19.0%, respec-
ively; HR, 0.55; 95% CI, 0.34-0.88; P  .01) and death
rom cardiovascular causes or MI (4.8% vs 10.1%, respec-
ively; HR, 0.47; 95% CI, 0.24-0.94; P  .03) compared
ith placebo.68 It may be advantageous to use the longer-
cting extended-release fluvastatin perioperatively in pa-
ients undergoing vascular surgery, since these patients may
ot receive any oral medications in the immediate postop-
rative period. Despite the multiple beneficial effects asso-
iated with perioperative statin use,9,66-68 there is evidence
hat less than two-thirds of patients undergoing vascular
urgery are on a statin preoperatively.69
Statins should be taken on the day of (or the evening
efore) surgery to maximize the potential benefit.70 It is
lso crucial that statin treatment be resumed as soon as
ossible after surgery.71 A study comparing cardiovascular
utcomes in patients resuming statin therapy 1 day after
ascular surgery with patients resuming treatment a median
f 4 days after vascular surgery showed that earlier statin
nitiation was associated with a 5.5-fold reduced risk for
ostoperative MI or elevated troponin levels (OR, 0.38 vs
.1; P  .001).71 Additionally, postoperative statin with-
rawal for4 days was associated with an almost threefold
ncreased risk for postoperative myocardial necrosis (OR,
.9; 95% CI, 1.6-5.5; P  .001).71
Recent evidence shows that a high loading dose prior to
ercutaneous coronary intervention (PCI) considerably re-
uces post-PCI myocardial injury and major adverse car-
iac events (MACEs).72,73 Extrapolating from these re-
ults, a single high-dose statin loading dose prior to an open
r endovascular procedure should reduce postprocedural
ACEs. This hypothesis, however, remains to be proven.
inally, it is important to develop intravenous statin formu-
as for the immediate postoperative period when patients
ay not receive oral medications.
TATINS AND VASCULAR DISEASES
According to the National Cholesterol Education
rogram–Adult Treatment Panel III (NCEP ATP III)
uidelines, PAD, AAAs, and carotid artery disease are con-
idered coronary heart disease equivalents.50 Therefore, the
arget LDL-C levels should be 100 mg/dL (2.6
mol/L) for these patients. For very high-risk patients, an
DL-C goal of 70 mg/dL (1.8 mmol/L) is “a therapeutic
e
n
a
t
b
w
o
n
w
s
s
C
v
a
v
G
a
f
s
e
e
e
m
i
a
i
n
r
m
p
A
C
A
D
W
C
F
S
O
O
R
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 3 Paraskevas et al 841option, ie, a reasonable clinical strategy on the basis of
available clinical evidence.”74
The beneficial effects of statins on AAAs, PAD, and
carotid artery disease are briefly described.
Statins and AAAs. Statins exert several beneficial ef-
fects in patients with AAAs.6,9 Several studies have sug-
gested that statins may retard AAA growth.6,75-77 A recent
meta-analysis concluded that statins are associated with a
reduction in AAA expansion rates (random-effects stan-
dardized mean difference, 0.50; 95% CI, 0.75 to
0.25; P  .0001).78 It was concluded that a large ran-
domized trial is required to confirm the results of this
meta-analysis. However, even if statins are not associated
with a reduction in AAA expansion rates, they are associ-
ated with improved perioperative morbidity and mortality
rates should these patients undergo open surgical9 or en-
dovascular7 AAA repair. Preoperative statin therapy is also
associated with a reduction in postoperative complications,
hospital length of stay, and total costs compared with statin
non-use.79 Thus, routine statin treatment should be imple-
mented in all AAA patients whether managed conserva-
tively or undergoing open surgical/endovascular AAA re-
pair.
Statins and carotid artery disease. Statins cause re-
gression/retard the progression of carotid intima-media
thickness and reduce the risk of stroke and combined
cardiovascular events.4 Statins also reduce the rate of mi-
croemboli as detected by transcranial Doppler in patients
with asymptomatic carotid stenosis.80 Furthermore, there
is evidence suggesting that statins are associated with im-
proved outcomes in patients undergoing carotid endarter-
ectomy or carotid artery stenting.81 Therefore, statins exert
several beneficial effects on patients with carotid artery
disease, whether managed conservatively or undergoing
carotid artery stenting/endarterectomy.
Statins and PAD. Statins increase walking distance
and reduce the incidence of cardiovascular events in pa-
tients with PAD.10,82,83 They also improve perioperative
mortality, graft patency, and limb salvage rates in these
patients.9,10,82,83 Finally, they improve the renal function
of these patients; impaired renal function is associated with
high morbidity and mortality rates, as well as the occur-
rence of cardiovascular events in PAD patients.84 Statin use
should therefore be routinely implemented in PAD pa-
tients.
ADHERENCE TO STATIN TREATMENT
Long-term adherence to statin treatment may be
poor.61-63 Nonadherence to statin treatment is a major
issue for the prevention and treatment of cardiovascular
diseases and is associated with high mortality. There is
evidence that “vascular” patients are undertreated with
respect to statins.61-63 Besides suboptimal statin treatment,
there is evidence of patient noncompliance;85 only half of
the patients prescribed statins continue taking them at 6
months, and only 30% to 40% continue taking them at 1
year.85 Physician–patient counseling on cardiovascular risk
and patient education programs may improve statin adher-nce.86 Increased physician follow-up and provider conti-
uity of care may also improve statin treatment compli-
nce.87 A study examining the level of patient awareness of
he benefits associated with statin use showed that 70%
elieved they had been using statins to decrease cholesterol,
hereas 16.5% stated that they had no idea why they were
n the drug.88 More than half of the participants (58%) did
ot know for how long they would need to use statins,
hereas only one in five patients (21%) replied that they
hould use them continuously. Finally, only one-fifth of the
tudy participants had some idea about side effects.88
ONCLUSIONS
Statins are an essential component of both the conser-
ative as well as the perioperative or periprocedural man-
gement of vascular patients. Based on current data, rosu-
astatin is the most potent statin followed by atorvastatin.
eneric formulations of these statins, however, are not yet
vailable. As a result of the recent introduction of generic
ormulations of simvastatin, lovastatin, and pravastatin, ro-
uvastatin and atorvastatin may not be the most cost-
ffective options. Intensive lipid lowering and pleiotropic
ffects of statins are associated with significantly more ben-
fits compared with standard care. The possible develop-
ent of statin-induced adverse effects due to higher doses
s counterbalanced by the greater clinical benefit. There are
number of strategies for continuing apparently statin-
ntolerant patients on some form of statin treatment. Fi-
ally, it is important to ensure that all vascular patients are
outinely on statin treatment and that this treatment is
aintained (or possibly increased) during the entire
eriprocedural period.
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